4 Biotech Stocks That Could Keep Beating Wall Street Zacks Equity Research - Zacks Investment Research - Mon Nov 11, 8:28AM CST Zacks Equity Research - ZACKS - Mon Nov 11, 8:28AM CST
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
Takeda Reports Solid Second Quarter FY2019 Results and Raises Profit Guidance for the Full Year BusinessWire - Thu Oct 31, 1:00AM CDT CMTX - Thu Oct 31, 1:00AM CDT
Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK):
Seattle Genetics (SGEN) Q3 Loss Widens, Revenues Top Mark Zacks Equity Research - Zacks Investment Research - Wed Oct 30, 11:29AM CDT Zacks Equity Research - ZACKS - Wed Oct 30, 11:29AM CDT
Seattle Genetics (SGEN) incurs wider-than-expected loss in third-quarter 2019 but rides high on revenue beat.
Easy Investing Secrets to an Early Retirement - October 11, 2019 Zacks Equity Research - Zacks Investment Research - Fri Oct 11, 8:37AM CDT Zacks Equity Research - ZACKS - Fri Oct 11, 8:37AM CDT
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments,...
Signs That Your Trading Will Ruin Your Retirement - October 09, 2019 Zacks Equity Research - Zacks Investment Research - Wed Oct 9, 8:39AM CDT Zacks Equity Research - ZACKS - Wed Oct 9, 8:39AM CDT
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Karyopharm Signs $150M Royalty Agreement to Support Xpovio Zacks Equity Research - Zacks Investment Research - Tue Sep 17, 9:39AM CDT Zacks Equity Research - ZACKS - Tue Sep 17, 9:39AM CDT
Karyopharm (KPTI) signs royalty agreement with HealthCare Royalty Partners for up to $150 million to fund Xpovio's commercialization and development.
Is Takeda (TAK) a Profitable Stock for Value Investors Now? Zacks Equity Research - Zacks Investment Research - Fri Aug 16, 8:30AM CDT Zacks Equity Research - ZACKS - Fri Aug 16, 8:30AM CDT
Let's see if Takeda (TAK) stock is a good choice for value-oriented investors right now from multiple angles.
Takeda Reports Strong First Quarter FY2019 Results and Raises Guidance for the Full Year BusinessWire - Wed Jul 31, 1:00AM CDT CMTX - Wed Jul 31, 1:00AM CDT
Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK):
How Do Earnings Impact The Stock Market? Panel Of Zacks Experts - Zacks Investment Research - Wed Jul 24, 2:29PM CDT Panel Of Zacks Experts - ZACKS - Wed Jul 24, 2:29PM CDT
Q2 Earnings Season is in full swing and Sheraz Mian joins the show to discuss everything you need to know!
GOOGL : 1,298.28 (-0.82%) Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates Zacks Equity Research - Zacks Investment Research - Wed Jul 17, 9:58AM CDT Zacks Equity Research - ZACKS - Wed Jul 17, 9:58AM CDT
Seattle Genetics (SGEN) betters loss estimates and rides high on revenue beat in Q2.
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire - Tue Jul 16, 12:15PM CDT CMTX - Tue Jul 16, 12:15PM CDT
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company")...
J&J Submits BLA for Subcutaneous Formulation of Darzalex Zacks Equity Research - Zacks Investment Research - Mon Jul 15, 4:59PM CDT Zacks Equity Research - ZACKS - Mon Jul 15, 4:59PM CDT
Johnson & Johnson (JNJ) submits a BLA to the FDA, seeking approval for a subcutaneous formulation of its multiple myeloma drug.
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire - Tue Jul 9, 10:30AM CDT CMTX - Tue Jul 9, 10:30AM CDT
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company")...
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire - Tue Jul 2, 10:30AM CDT CMTX - Tue Jul 2, 10:30AM CDT
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company")...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK GlobeNewswire - Mon Jul 1, 3:32PM CDT CMTX - Mon Jul 1, 3:32PM CDT
Pomerantz LLP is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or the "Company") (NYSE: TAK). Such investors are advised to contact Robert S. Willoughby...
Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status Zacks Equity Research - Zacks Investment Research - Mon Jul 1, 8:26AM CDT Zacks Equity Research - ZACKS - Mon Jul 1, 8:26AM CDT
The FDA grants orphan drug designation to Arcturus Therapeutics' (ARCT) candidate, ARCT-810 for treating patients with ornithine transcarbamylase deficiency, the most common urea cycle disorder.
J&J's Darzalex Gets FDA Nod for First-Line Multiple Myeloma Zacks Equity Research - Zacks Investment Research - Fri Jun 28, 3:01PM CDT Zacks Equity Research - ZACKS - Fri Jun 28, 3:01PM CDT
Johnson & Johnson's (JNJ) label expansion application, seeking approval for Darzalex+Revlimid to treat transplant ineligible newly diagnosed patients with multiple myeloma, receives FDA approval.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK PR Newswire - Fri Jun 28, 2:13PM CDT CMTX - Fri Jun 28, 2:13PM CDT
Pomerantz LLP is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or the "Company") (NYSE: TAK). Such investors are advised to contact Robert S. Willoughby...
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm BusinessWire - Thu Jun 27, 5:45PM CDT CMTX - Thu Jun 27, 5:45PM CDT
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company")...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm BusinessWire - Tue Jun 25, 6:22PM CDT CMTX - Tue Jun 25, 6:22PM CDT
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company")...
